Study of Effect of Vaginal ph and Acidification of Vaginal Misoprostol on Its Efficacy for Induction of Midtrimester Abortion
NCT ID: NCT01241045
Last Updated: 2010-11-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2010-11-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. A formal consent from the women under study with full notification and explanation of the methods, importance of the study and possible unwanted effects.
2. During the pre-selection visit, exclusion and inclusion criteria will be applied. Baseline investigations; Blood sugar, Serum Glutamate Oxaloacetate Transaminase (SGOT), Serum Glutamate Pyruvate Transaminase (SGPT), S. Creatinine, and Complete Blood Count (C.B.C.) and Coagulation profile (PTT, serum fibrinogen level) will be done.
3. Following admission, all patients will undergo complete clinical examination and detailed medical history will be obtained. Each patient will have a Case Record Form (CRF) in which the following data will be recorded.
* Patient initials.
* Patient number (according to the randomization schedule).
* Age, height, weight,
* Known allergies.
* Past medical and surgical history (no longer present).
* Medications taken within the last 4 weeks and discontinued.
* Concomitant illnesses.
* Concomitant medications which will not be discontinued.
* Clinical examination: including full gynaecologic assessment including vaginal and speculum examination with recording of vaginal and cervical condition.
4. The vaginal Ph will be measured using Universal indicator paper pH (1-14) before digital vaginal examination. Through speculum examination, the indicator will be held with an artery forceps against the vaginal wall-high up in the vagina-until it becomes wet.
Color change of the strip will be immediately compared with the colorimetric scale and the measurement will be recorded.
Patients will be divided into 2 groups:-
* Group 1:-those with Ph\<5. (n=50).
* Group 2:-those with Ph \> or=5. (n=50).
5. Each group is subdivided into another two groups:-
* Group 1A (n=25). - Group 1B (n=25).
* Group 2A (n=25). - Group 2B (n=25).
6. All the women in group 1A and group 2A will receive intravaginal misoprostol tablets moistened with 3 ml of 5% acetic acid, and all the women in group 1B and group 2B will receive intravaginal misoprostol tablets moistened with water, 400 micrograms every 4 hours for a maximum of 5 doses within 24 hours. If the patient will not have adequate uterine contractions, the same regimen will be repeated over the following 24 hours, and if no response will be achieved, this will be considered a failure of therapy, and another method will be used like large doses of oxytocin or cervical dilatation by foley's catheter no.16.
7. assessment will be though the occurrence of uterine contraction and progress of abortion with induction -termination interval as a primary outcome.
8. The investigator will supervise application of the medication dose by dose. Subjects withdrawn from the study before the onset of spontaneous labor
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
misoprostol
2 groups:-
* Group 1:-those with Ph\<5. (n=50).
* Group 2:-those with Ph \> or=5. (n=50). -Each group is subdivided into another two groups:-
* Group 1A (n=25). - Group 1B (n=25).
* Group 2A (n=25). - Group 2B (n=25).
* All the women in group 1A and group 2A will receive intravaginal misoprostol tablets moistened with 3 ml of 5% acetic acid, and all the women in group 1B and group 2B will receive intravaginal misoprostol tablets moistened with water, 400 micrograms every 4 hours for a maximum of 5 doses within 24 hours. If the patient will not have adequate uterine contractions, the same regimen will be repeated over the following 24 hours
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A valid indication for termination of pregnancy.
3. Singleton pregnancy.
4. Gestational age ranging between 14 and 26 weeks of pregnancy.
5. Uterus and cervix are apparently normal on clinical examination.
6. Cervix is not dilated with absence of effacement.
7. Absence of uterine activity.
8. Written and signed informed consent by the patient to participate in the study.
Exclusion Criteria
2. Evidences suggesting onset of spontaneous abortion (uterine contractions with or without cervical changes).
3. Previous trial to induce abortion or the use of pre-induction agent during the current pregnancy.
4. Any contraindication to receiving prostaglandins, including known hypersensitivity to misoprostol or other prostaglandins (PGs), history of asthma, glaucoma, cardiac or cardiovascular disease.
5. Parity six or more.
6. Multifetal pregnancy.
7. Severe Polyhydramnios.
8. Presence of vaginal bleeding.
9. Presence of ruptured membranes and/or suspicion of septic abortion as evidenced by maternal temperature of 38°C or more, uterine tenderness or foul-smelling vaginal discharge.
10. Previous Caesarean section or other uterine surgery or perforation.
11. Cervical cerclage during current pregnancy, or history of it during a previous pregnancy.
12. Previous cervical surgery as cauterization of cervical erosion or cervical dilatation operation with resultant apparent cervical tears or lacerations.
13. Metabolic acidosis as a result of a medical disorder.
14. Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol which include all vaginal forms of medications.
15 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams
Cairo, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AubshamsU
Identifier Type: -
Identifier Source: org_study_id